Brandon E Kremer
Overview
Explore the profile of Brandon E Kremer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
730
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sunami K, Iida S, Tsukada N, Fujii T, Kato H, Fukushima R, et al.
Int J Hematol
. 2024 Dec;
121(2):174-186.
PMID: 39718747
DREAMM-11 (NCT03828292) was a Phase 1, open-label, dose-escalation study of belantamab mafodotin in Japanese patients with relapsed/refractory multiple myeloma (RRMM). In Part 1, belantamab mafodotin monotherapy (2.5 or 3.4 mg/kg...
2.
Watts J, Minden M, Bachiashvili K, Brunner A, Abedin S, Crossman T, et al.
Ther Adv Hematol
. 2024 Sep;
15:20406207241275376.
PMID: 39290981
Background: GSK3326595 is a potent, selective, reversible protein arginine methyltransferase 5 (PRMT5) inhibitor under investigation for treatment of myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML), and acute myeloid leukemia (AML)....
3.
Dimopoulos M, Beksac M, Pour L, Delimpasi S, Vorobyev V, Quach H, et al.
N Engl J Med
. 2024 Jun;
391(5):408-421.
PMID: 38828951
Background: Triplet or quadruplet therapies incorporating proteasome inhibitors, immunomodulators, and anti-CD38 antibodies have led to prolonged survival among patients with newly diagnosed multiple myeloma; however, most patients have a relapse....
4.
Iida S, Sunami K, Mishima Y, Fujii T, Kato H, Terao T, et al.
Int J Hematol
. 2023 Sep;
118(5):596-608.
PMID: 37668832
Belantamab mafodotin, a B-cell maturation antigen-targeting antibody-drug conjugate (ADC), was investigated in Japanese patients with relapsed/refractory multiple myeloma in Part 1 of the phase I DREAMM-11 study. Patients who had...
5.
Ficek J, Kalaitzaki E, Yuan S, Tosolini A, Du L, Kremer B, et al.
Clin Lymphoma Myeloma Leuk
. 2023 Mar;
23(5):e213-e221.
PMID: 36907767
Current frontline therapies for newly diagnosed multiple myeloma patients have significantly prolonged progression-free survival (PFS). This has led to interest in minimal residual disease negativity (MRDng) as an efficacy-response biomarker...
6.
Dawson M, Borthakur G, Huntly B, Karadimitris A, Alegre A, Chaidos A, et al.
Clin Cancer Res
. 2022 Nov;
29(4):711-722.
PMID: 36350312
Purpose: Molibresib is a selective, small molecule inhibitor of the bromodomain and extra-terminal (BET) protein family. This was an open-label, two-part, Phase I/II study investigating molibresib monotherapy for the treatment...
7.
Cousin S, Blay J, Garcia I, de Bono J, Le Tourneau C, Moreno V, et al.
Int J Cancer
. 2021 Nov;
150(6):993-1006.
PMID: 34724226
Molibresib is an orally bioavailable, selective, small molecule BET protein inhibitor. Results from a first time in human study in solid tumors resulted in the selection of a 75 mg...
8.
Nooka A, Weisel K, van de Donk N, Routledge D, Otero P, Song K, et al.
Future Oncol
. 2021 Mar;
17(16):1987-2003.
PMID: 33682447
Belantamab mafodotin (belamaf) is a BCMA-targeted antibody-drug conjugate recently approved as monotherapy for adults with relapsed/refractory multiple myeloma who have received ≥4 prior therapies. Belamaf binds to BCMA and eliminates...
9.
Riddell K, Patel A, Collins G, Zhou Y, Schramek D, Kremer B, et al.
J Clin Pharmacol
. 2020 Aug;
61(1):125-137.
PMID: 32820548
Molibresib (GSK525762), an orally bioavailable small molecule with 2 major equipotent active metabolites, is being developed for the treatment of cancers. Molibresib is a substrate of cytochrome P450 (CYP) 3A4...
10.
Bell C, Fennell K, Chan Y, Rambow F, Yeung M, Vassiliadis D, et al.
Nat Commun
. 2019 Jun;
10(1):2723.
PMID: 31222014
Non-genetic drug resistance is increasingly recognised in various cancers. Molecular insights into this process are lacking and it is unknown whether stable non-genetic resistance can be overcome. Using single cell...